Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of ZG005 in Patients With Advanced Solid Tumors
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
This is a multi-center, open-label, Phase 1/2 study of ZG005 for the treatment of subjects with advanced solid tumors, and consists of three stages: dose escalation and confirmation of MTD/recommended dose.
Official title: A Phase 1/2 Dose Escalation, Tolerability, Safety and Pharmacokinetics Study of ZG005 in Patients With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
484
Start Date
2022-06-17
Completion Date
2026-01
Last Updated
2024-06-14
Healthy Volunteers
No
Conditions
Interventions
ZG005 Powder for Injection
The dose groups of ZG005 for dose escalations are set as 0.3 mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, and 20mg/kg, intravenous infusion, once every 3 weeks.
ZG005 Powder for Injection
Recommended Phase 2 Dose (RP2D) of ZG005 monotherapy, intravenous infusion, once every 3 weeks.
Locations (1)
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China